Comparative Pharmacology
Head-to-head clinical analysis: FRINDOVYX versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FRINDOVYX versus HICON.
FRINDOVYX vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Frindovyx is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
10 mg orally once daily.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 48 hours in severe impairment (CrCl <30 mL/min).
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 30% recovered as inactive metabolites in urine. Fecal/biliary elimination constitutes the remaining 10%.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic
Anticholinergic